Clearside Biomedical, Inc. (CLSD): Price and Financial Metrics


Clearside Biomedical, Inc. (CLSD): $3.01

-0.10 (-3.22%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CLSD POWR Grades


  • Sentiment is the dimension where CLSD ranks best; there it ranks ahead of 55.95% of US stocks.
  • CLSD's strongest trending metric is Growth; it's been moving down over the last 31 weeks.
  • CLSD ranks lowest in Momentum; there it ranks in the 5th percentile.

CLSD Stock Summary

  • The ratio of debt to operating expenses for Clearside Biomedical Inc is higher than it is for about just 7.6% of US stocks.
  • With a price/sales ratio of 43.44, Clearside Biomedical Inc has a higher such ratio than 94.04% of stocks in our set.
  • With a year-over-year growth in debt of -85.64%, Clearside Biomedical Inc's debt growth rate surpasses just 2.59% of about US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Clearside Biomedical Inc are DYAI, PSNL, RAPT, TUFN, and PRQR.
  • CLSD's SEC filings can be seen here. And to visit Clearside Biomedical Inc's official web site, go to www.clearsidebio.com.

CLSD Price Target

For more insight on analysts targets of CLSD, see our CLSD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.38 Average Broker Recommendation 1.4 (Strong Buy)

CLSD Stock Price Chart Interactive Chart >

Price chart for CLSD

CLSD Price/Volume Stats

Current price $3.01 52-week high $4.53
Prev. close $3.11 52-week low $1.25
Day low $3.01 Volume 71,800
Day high $3.17 Avg. volume 503,086
50-day MA $2.72 Dividend yield N/A
200-day MA $2.46 Market Cap 173.31M

Clearside Biomedical, Inc. (CLSD) Company Bio


Clearside Biomedical, a biopharmaceutical company, develops drug therapies to treat chronic blinding diseases of the eye. The company was founded in 2011 and is based in Alpharetta, Georgia


CLSD Latest News Stream


Event/Time News Detail
Loading, please wait...

CLSD Latest Social Stream


Loading social stream, please wait...

View Full CLSD Social Stream

Latest CLSD News From Around the Web

Below are the latest news stories about Clearside Biomedical Inc that investors may wish to consider to help them evaluate CLSD as an investment opportunity.

Clearside Biomedical to Participate in Two Upcoming Investor Conferences in June 2021

ALPHARETTA, Ga., June 09, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer, and Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer, will participate in two upcoming investor conferences in June 2021:

Yahoo | June 9, 2021

Bausch Health And Clearside Biomedical Announce U.S. FDA Filing Acceptance For XIPERE™ (triamcinolone acetonide suprachoroidal injectable suspension)

Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and Bausch + Lomb, its leading global eye health business, along with Clearside Biomedical, Inc. (Nasdaq: CLSD) ("Clearside"), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that the U.S. Food and Drug Administration (FDA) has accepted the resubmitted New Drug Application for XIPERE™1 (triamcinolone aceton

Yahoo | June 2, 2021

Clearside Biomedical, Inc. (CLSD) CEO George Lasezkay on Q1 2021 Results - Earnings Call Transcript

Clearside Biomedical, Inc. (CLSD) Q1 2021 Earnings Conference Call May 17, 2021 04:30 PM ET Company Participants Jenny Kobin - Head of Investor Relations George Lasezkay - President, Chief Executive Officer Thomas Ciulla - Chief Medical Officer and Chief Development Officer Charles Deignan - Chief Financial Officer Conference Call Participants...

SA Transcripts on Seeking Alpha | May 18, 2021

Clearside Biomedical to Report First Quarter 2021 Financial Results and Provide Corporate Update on Monday, May 17, 2021

ALPHARETTA, Ga., May 04, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that its first quarter 2021 financial results will be reported on Monday, May 17, 2021 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. The live call can be accessed by dialing (844) 263-8310 (domestic) or (213) 358-0959 (international) and entering conference code: 1488886. A...

Yahoo | May 4, 2021

Clearside Biomedical to Present at the Needham Virtual Healthcare Conference and Wet AMD & DME Drug Development Summit

ALPHARETTA, Ga., April 05, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer, will present at two upcoming virtual conferences in April 2021: Needham Virtual Healthcare Conference Monday, April 12, 2021 at 12:45 p.m. ET The live and archived Needham Virtual Healthcare Conference presentation webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. Wet AMD & DME Drug Development Summit Wednesday, April 14, 2021Event details are available on the conference website. 10...

Yahoo | April 5, 2021

Read More 'CLSD' Stories Here

CLSD Price Returns

1-mo 29.74%
3-mo -1.31%
6-mo 44.71%
1-year 52.02%
3-year -70.29%
5-year -56.38%
YTD 9.85%
2020 -5.52%
2019 171.03%
2018 -84.71%
2017 -21.70%
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8397 seconds.